Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: Micardis®; Drug: MicardisPlus®

Study type: Observational

Funder types: Industry

Identifiers

NCT02242825

502.505

Details and patient eligibility

About

The primary objective is to evaluate the effect of the treatment with Micardis® or MicardisPlus® on blood pressure. Secondary objectives are the effect of Micardis® / MicardisPlus® on metabolic parameters (triglycerides, cholesterol, blood glucose and HbA1c) in patients with essential hypertension and diabetes mellitus

Enrollment: 8,148 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years
• Hypertension
• Diabetes mellitus

Exclusion criteria

• Age < 18 years

Trial design

8,148 participants in 1 patient group

Patients with hypertension and diabetes mellitus

Treatment:

Drug: MicardisPlus®

Drug: Micardis®